title: Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
authors.affiliation: Department of Dermatology, Venereology, and Allergology, Ruhr University Bochum, DE-44791 Bochum, Germany. n.patsinakidis@klinikum-bochum.de.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Patsinakidis
authors.forename: Alexander
authors.initials: A
authors.lastname: Kreuter
authors.forename: Rose K C
authors.initials: RK
authors.lastname: Moritz
authors.forename: Markus
authors.initials: M
authors.lastname: Stücker
authors.forename: Peter
authors.initials: P
authors.lastname: Altmeyer
authors.forename: Katrin
authors.initials: K
authors.lastname: Möllenhoff
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012883:Skin Ulcer / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin